Release issued 12th September 2007

September 12, 2007, Waltham, Mass.  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of Merck's Proscar, Boehringer Ingelheim's Flomax, and Astellas's Omix, combined with the limited emergence of new therapies, will cause a 23% decline in sales of therapies to treat benign Prostatic Hyperplasia over the next five years.

The new Pharmacor report entitled Benign Prostatic Hyperplasia finds that the market to treat the disease is dominated by two drug classes-alpha blockers and 5-alpha-reductase inhibitors-which make up 93% of drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. Boehringer Ingelheim's Flomax and Astellas's Omix (both alpha blockers) dominated the market in 2006, comprising half of all benign Prostatic Hyperplasia drug sales. However, the patent expiries of Proscar, Flomax, Omix, and GlaxoSmithKline's Avodart in the United States in 2009 will cause a significant decline in the overall benign Prostatic Hyperplasia market by 2011.

Although patent expiries will constrain the market in the near term, increases in the patient population, unmet need, and higher drug treatment rates from 2011 to 2016 will help create a favorable landscape for novel benign Prostatic Hyperplasia treatments.

"Eli Lilly's Cialis and GlaxoSmithKline's fixed-dose combination of Tamsulosin and Dutasteride, both of which are expected to launch for benign Prostatic Hyperplasia in the United States and in Europe by 2011, are the two most promising agents in the pipeline," said Greg Dwyer, analyst at Decision Resources. "The combined sales of these two drugs will represent nearly 30% of the total benign Prostatic Hyperplasia market in 2016."

About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread